MINNEAPOLIS, Sept. 26, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding ...

Uroplasty announced that ConnectiCare of the Emblem Health family of insurers began coverage of percutaneous tibial nerve stimulation, or PTNS, using its Urgent PC neuromodulation system for the ...

SAN FRANCISCO—Patients with overactive bladder (OAB) who respond well to 12 weeks therapy with a percutaneous tibial nerve stimulation (PTNS) device are likely to have sustained improvement at 12 ...

Overactive bladder (OAB) is defined as urinary urgency, with or without urge incontinence, often with frequency and nocturia. Initial therapy of OAB often includes anticholinergics and behavioral ...

This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. The procedure is ideal in this population because it is minimally invasive and highly efficacious The ...

Uroplasty UPI, a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by ...

This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and ...